Moderate

Crohn's disease — maintenance & biologic therapy

Crohn's maintenance · Gastroenterology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Transmural, potentially stricturing/penetrating disease requiring maintenance immunosuppression after induction. Early advanced therapy ('top-down') is favoured in high-risk patients to prevent complications and surgery.

Red flags

  • Obstructive symptoms (stricture)
  • Abdominal mass, fever, or features of abscess/fistula
  • Significant weight loss / failure to thrive
  • New perianal sepsis

Assessment

Differential diagnosis

  • Ulcerative colitis
  • Intestinal TB / Yersinia
  • Behçet's disease
  • NSAID enteropathy
  • Ischaemic/segmental colitis
  • Lymphoma
  • Functional symptoms overlapping remission

Investigations

  • Faecal calprotectin for monitoring
  • CRP, FBC, albumin, ferritin, B12, vitamin D
  • Colonoscopy/ileoscopy with biopsy for mucosal healing
  • MR enterography for small-bowel/stricturing/penetrating disease
  • Thiopurine metabolites; therapeutic drug monitoring of biologics
  • Hepatitis B/C, TB (IGRA), VZV before immunosuppression

Management

  • Define phenotype (inflammatory, stricturing, penetrating) and location; identify high-risk features (young, deep ulcers, perianal, early surgery)
  • Assess prognosis — favour early advanced therapy in high-risk disease
  • Do NOT use 5-ASA as effective Crohn's maintenance (limited efficacy)
  • Use a thiopurine or methotrexate as immunomodulator, often combined with a biologic
  • Start a biologic — anti-TNF (infliximab/adalimumab), ustekinumab, vedolizumab, or risankizumab
  • Complete infection screening and vaccination before starting immunosuppression
  • Stop smoking — the single most important modifiable factor in Crohn's
  • Target deep remission (symptomatic + biochemical/endoscopic healing); use therapeutic drug monitoring
  • Image strictures to distinguish inflammatory from fibrotic before escalating vs endoscopic/surgical treatment
  • Replace micronutrient deficiencies (iron, B12, vitamin D) and optimise nutrition
  • Plan post-operative prophylaxis after resection and ongoing surveillance

Drugs & doses

Azathioprine 2–2.5 mg/kg PO once daily
Methotrexate 15–25 mg SC/IM once weekly (with folic acid 5 mg weekly)
Infliximab 5 mg/kg IV at 0, 2, 6 weeks then 8-weekly
Adalimumab 160/80 mg SC induction then 40 mg every 2 weeks
Ustekinumab IV weight-based induction then 90 mg SC every 8 weeks
Risankizumab 600 mg IV induction then 360 mg SC maintenance

Disposition

Specialist IBD clinic with MDT (radiology, surgery, dietitian) and nurse-led biologic monitoring.

Complications & pitfalls

  • Fibrotic strictures and obstruction
  • Fistulae and intra-abdominal abscess
  • Malnutrition and micronutrient deficiency
  • Opportunistic infection and lymphoma risk from immunosuppression
  • Short-bowel syndrome after repeated resection

Exam pearls

  • 5-ASA is ineffective for Crohn's maintenance — reserve the immunomodulators and biologics
  • Early 'top-down' biologic therapy in high-risk disease reduces complications and surgery
  • Smoking cessation is as important as any drug in Crohn's
  • MR enterography differentiates inflammatory (treatable) from fibrotic (needs dilatation/surgery) strictures

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.